跳至主要内容
临床试验/JPRN-jRCT2052230047
JPRN-jRCT2052230047暂停3 期

Thoracic Stent-Graft System TCD-11226; A non-blind multicenter clinical trial

Sugisaki Shunichiro0 个研究点目标入组 42 人开始时间: 2023年6月21日最近更新:
适应症

试验速览

阶段
3 期
状态
暂停
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Age is >= 18 years at the time of informed consent.
  • 2. Patients considered suitable for TEVAR using thoracic stent-graft system TCD-11226 after comprehensive evaluation of risk factors and consideration of other treatment options.
  • 3. Patients with a minimum inner diameter of the central landing zone of the TCD-11226 main stent-graft of 28 mm or larger.
  • 4. Patients with no dissection in BCT and LCCA, which are landing zones of the TCD-11226 branch stent-graft.
  • 5. Patients with femoral/iliac artery diameter accessible with 25 Fr delivery catheter.

排除标准

  • 1. Patients with inaccessible access from the femoral or iliac artery.
  • 2. Patients with difficult-to-pass stenosis or Grade 2 or higher atherosclerotic thrombosis in the TCD-11226 branch stent-graft device approach vessel.
  • 3. Patients with Grade 2 or higher atherosclerotic thrombosis at the landing zone of the TCD-11226 branch stent-graft.
  • 4. Patients who have had symptomatic stroke or cerebral hemorrhage within 6 months prior to trial registration.
  • 5. Patients who have participated in another clinical trial of a pharmaceutical product or medical device within 1 year prior to trial registration.

研究者

发起方
Sugisaki Shunichiro

相似试验